← Back to Search

Neurofeedback for Schizophrenia

N/A
Waitlist Available
Research Sponsored by University of California, San Diego
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of schizophrenia/schizoaffective disorder
Be older than 18 years old
Must not have
History of seizure disorder
Timeline
Screening 3 weeks
Treatment Varies
Follow Up this variable will be assessed at t=0, 4 weeks, 8 weeks, 12 weeks and 4 weeks post completion of intervention
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a computer-based brain training program called Gamma Neurofeedback (G-NFB) for patients with schizophrenia. It aims to improve their memory and cognitive function by helping their brains synchronize better. If successful, it could offer a new way to treat cognitive deficits in these patients.

Who is the study for?
This trial is for individuals diagnosed with schizophrenia or schizoaffective disorder. It's not suitable for pregnant individuals, those who've changed medications in the last month, have a history of traumatic brain injury, active substance use disorders within the past month, or a seizure disorder.
What is being tested?
The study is testing a new computer-based brain training program designed to improve working memory in patients with schizophrenia. The goal is to see if this neurofeedback intervention can lead to better outcomes and quality of life.
What are the potential side effects?
Since the intervention involves non-invasive computer exercises, there are no direct physical side effects like you might expect from medication. However, participants may experience fatigue or frustration.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with schizophrenia or schizoaffective disorder.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a history of seizures.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~this variable will be assessed at t=0, 4 weeks, 8 weeks, 12 weeks and 4 weeks post completion of intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and this variable will be assessed at t=0, 4 weeks, 8 weeks, 12 weeks and 4 weeks post completion of intervention for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Task related Gamma band response (gamma coherence and power)
Secondary study objectives
Change in Working memory

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Schizophrenia patientsExperimental Treatment1 Intervention
Thirty SCZ patients will receive neurofeedback to enhance gamma band response in an open-label, proof of concept study.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for schizophrenia include antipsychotic medications, which primarily work by blocking dopamine receptors to reduce psychotic symptoms, and cognitive behavioral therapy (CBT), which helps patients manage symptoms and improve functioning through structured psychological interventions. Newer treatments, such as computer-based brain training, aim to enhance cognitive functions like working memory by engaging patients in targeted mental exercises. These treatments are crucial for schizophrenia patients as they address both the psychotic symptoms and the cognitive deficits that significantly impact daily functioning and long-term outcomes.

Find a Location

Who is running the clinical trial?

University of California, San DiegoLead Sponsor
1,177 Previous Clinical Trials
1,573,534 Total Patients Enrolled
28 Trials studying Schizophrenia
5,860 Patients Enrolled for Schizophrenia
National Institutes of Health (NIH)NIH
2,810 Previous Clinical Trials
8,159,568 Total Patients Enrolled
12 Trials studying Schizophrenia
1,594 Patients Enrolled for Schizophrenia

Media Library

Neurofeedback Clinical Trial Eligibility Overview. Trial Name: NCT03260257 — N/A
Schizophrenia Research Study Groups: Schizophrenia patients
Neurofeedback 2023 Treatment Timeline for Medical Study. Trial Name: NCT03260257 — N/A
~8 spots leftby Nov 2025